Severity: Warning
Message: file_get_contents(https://...@gmail.com&api_key=61f08fa0b96a73de8c900d749fcb997acc09&a=1): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests
Filename: helpers/my_audit_helper.php
Line Number: 197
Backtrace:
File: /var/www/html/application/helpers/my_audit_helper.php
Line: 197
Function: file_get_contents
File: /var/www/html/application/helpers/my_audit_helper.php
Line: 271
Function: simplexml_load_file_from_url
File: /var/www/html/application/helpers/my_audit_helper.php
Line: 3165
Function: getPubMedXML
File: /var/www/html/application/controllers/Detail.php
Line: 597
Function: pubMedSearch_Global
File: /var/www/html/application/controllers/Detail.php
Line: 511
Function: pubMedGetRelatedKeyword
File: /var/www/html/index.php
Line: 317
Function: require_once
98%
921
2 minutes
20
3D-DXA, as implemented in the software tool 3D-Shaper, is a software method that generates a 3D reconstruction of the proximal femur from a single 2D DXA image by registering a statistical model. Implementations of 3D-DXA aim to provide estimates of trabecular, cortical, and structural parameters, similar to those derived from quantitative computed tomography (QCT). As the inventor and developer of the software methods upon which 3D-DXA is built, I have been observing its adoption and widespread use with increasing concern. This article provides a critical evaluation of the methodological limitations inherent to 3D-DXA and discusses their implications for research and patient care. The primary issue is that the limited visibility of the cortex in a DXA image prevents 3D-DXA from accurately deriving cortical parameters. Instead, the software relies on predictions based on overall BMD rather than direct cortical measurements. This may lead to results that do not reflect actual cortical measurements. Additional concerns include the population bias due to the statistical model being derived from a specific demographic, and limited reconstruction accuracy by using single-view DXA images. These limitations have likely resulted in incorrect measurements and research outcomes, which have largely gone unrecognized due to the use of inappropriate performance assessment metrics and the absence of multiple comparison corrections in studies involving 3D-DXA. Despite these limitations, 3D-DXA has received regulatory approval in various countries, potentially compromising the accuracy of clinical diagnoses and treatment decisions. By highlighting these issues, this article aims to inform clinicians, researchers, and regulatory bodies about the significant limitations of 3D-DXA. It underscores the urgent need for a reevaluation of its use in research and clinical settings to prevent misinterpretation of results and to ensure patient safety.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12319322 | PMC |
http://dx.doi.org/10.1093/jbmrpl/ziaf075 | DOI Listing |